Thomas F. Isett

Chief Executive Officer & Chairman of the Board

Prior to becoming CEO for iBio in March 2020, Mr. Isett played an integral part in reshaping the Company’s strategy and operations in his role as Board Member and Strategic Advisor since April 2019. He was able to contribute his deep management and strategic insights via the consulting firm he founded in 2015, i.e. Advising, LLC, which supported Fortune 500s, institutional investors, biotechs and non-profits alike with M&A, turnarounds, and more. 

Previously, he ran business units for GE, Lonza, and BD, ranging in size from start-up to a half billion in revenues. Notably, he founded BD Advanced Bioprocessing (which sold to ThermoFisher in 2018 for $477M), and Commence Bio, Inc. a cellular immunotherapy company. Mr. Isett received his B.Sc. degree with Honors in Biological Sciences from Drexel University.

Robert L. Erwin


Robert L. Erwin previously led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive Chairman until 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC providing consulting services to the life sciences industry. He served as Chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. He is currently Chairman of Novici Biotech, a private biotechnology company and a Director of Resolve Therapeutics LLC. Mr. Erwin's non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder and President of the Marti Nelson Cancer Foundation, and a member of the Cancer Policy Forum of the Institute of Medicine. Mr. Erwin received his B.S. degree with Honors in Zoology and an M.S. degree in Genetics from Louisiana State University.